药物之间的相互作用1329045个记录(本栏目收费,不能展示细节,电话13136136841)
药物之间的相互作用
Tiludronic acid
Landogrozumab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Landogrozumab.
Tiludronic acid
Seribantumab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Seribantumab.
Tiludronic acid
Ligelizumab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Ligelizumab.
Tiludronic acid
Ublituximab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Ublituximab.
Tiludronic acid
Emibetuzumab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Emibetuzumab.
Tiludronic acid
Dalotuzumab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Dalotuzumab.
Tiludronic acid
Guselkumab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Guselkumab.
Tiludronic acid
Lampalizumab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Lampalizumab.
Tiludronic acid
Sirukumab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Sirukumab.
Tiludronic acid
Brodalumab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Brodalumab.
Tiludronic acid
Tremelimumab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Tremelimumab.
Tiludronic acid
Sarilumab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Sarilumab.
Tiludronic acid
Solanezumab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Solanezumab.
Tiludronic acid
Onartuzumab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Onartuzumab.
Tiludronic acid
Depatuxizumab mafodotin
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Depatuxizumab mafodotin.
Tiludronic acid
Bapineuzumab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Bapineuzumab.
Tiludronic acid
Durvalumab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Durvalumab.
Tiludronic acid
Figitumumab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Figitumumab.
Tiludronic acid
Ficlatuzumab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Ficlatuzumab.
Tiludronic acid
Tabalumab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Tabalumab.